ES3035604T3 - Forms and compositions of inhibitors of plasma kallikrein - Google Patents

Forms and compositions of inhibitors of plasma kallikrein

Info

Publication number
ES3035604T3
ES3035604T3 ES21724430T ES21724430T ES3035604T3 ES 3035604 T3 ES3035604 T3 ES 3035604T3 ES 21724430 T ES21724430 T ES 21724430T ES 21724430 T ES21724430 T ES 21724430T ES 3035604 T3 ES3035604 T3 ES 3035604T3
Authority
ES
Spain
Prior art keywords
compound
pattern
solid form
xrpd
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21724430T
Other languages
English (en)
Spanish (es)
Inventor
Suresh Kumar Tipparaju
Jeffrey Scott Depue
Helge Alfred Reisch
Samuel Alexander Stratford
Joseph Stephen Harris
Sarah Jocelyn Fink
Nikolaos Papaioannou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES3035604T3 publication Critical patent/ES3035604T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES21724430T 2020-04-17 2021-04-16 Forms and compositions of inhibitors of plasma kallikrein Active ES3035604T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011776P 2020-04-17 2020-04-17
PCT/US2021/027620 WO2021211930A1 (en) 2020-04-17 2021-04-16 Forms and compositions of inhibitors of plasma kallikrein

Publications (1)

Publication Number Publication Date
ES3035604T3 true ES3035604T3 (en) 2025-09-05

Family

ID=75870731

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21724430T Active ES3035604T3 (en) 2020-04-17 2021-04-16 Forms and compositions of inhibitors of plasma kallikrein

Country Status (9)

Country Link
US (1) US20230167132A1 (https=)
EP (2) EP4623913A3 (https=)
JP (2) JP2023522331A (https=)
DK (1) DK4136091T3 (https=)
ES (1) ES3035604T3 (https=)
FI (1) FI4136091T3 (https=)
PL (1) PL4136091T3 (https=)
PT (1) PT4136091T (https=)
WO (1) WO2021211930A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028362A1 (en) * 2017-08-04 2019-02-07 Dyax Corp. INHIBITORS OF PLASMATIC KALLIKREIN AND USES THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
EP1596869B1 (en) * 2003-01-21 2014-06-04 New Form Pharmaceuticals Inc. Novel cocrystallization
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
CN110015955A (zh) * 2010-07-23 2019-07-16 格吕伦塔尔有限公司 3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚的盐或共晶体
WO2012097333A2 (en) * 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
EP3765459A1 (en) 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Also Published As

Publication number Publication date
PL4136091T3 (pl) 2025-08-18
WO2021211930A1 (en) 2021-10-21
EP4136091A1 (en) 2023-02-22
EP4136091B1 (en) 2025-05-28
FI4136091T3 (fi) 2025-07-25
EP4623913A2 (en) 2025-10-01
US20230167132A1 (en) 2023-06-01
WO2021211930A8 (en) 2021-12-16
JP2023522331A (ja) 2023-05-30
JP2025142238A (ja) 2025-09-30
PT4136091T (pt) 2025-08-22
EP4623913A3 (en) 2025-12-24
DK4136091T3 (da) 2025-08-18

Similar Documents

Publication Publication Date Title
ES2371549T3 (es) Montelukast en estado sólido.
KR101327780B1 (ko) Ｒｈｏ 키나제 억제제로서의 이소퀴놀린 유도체
ES2698298T3 (es) Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
US10752607B2 (en) Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors
KR20130122031A (ko) Ｈｉｖ 인테그라제 억제제의 칼륨 염
JP2009544602A (ja) サイクリン依存性キナーゼ阻害剤の医学的使用
WO2020001420A1 (zh) 一类细胞坏死抑制剂及其制备方法和用途
TW200306809A (en) Compounds for the treatment of inflammatory disorders
KR102233081B1 (ko) 〔[1-시아노-5-(4-클로로페녹시)-4-하이드록시-아이소퀴놀린-3-카보닐]-아미노〕-아세트산의 결정 형태
ES2993711T3 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
RU2507203C1 (ru) Соединение, некоторые его новые формы, фармацевтические композиции на его основе и способы получения и применения
US20240174669A1 (en) Crystalline forms of a parp1 inhibitor
CN110012667A (zh) 化合物(2S，3R)-2-(((2-(1，5-二甲基-6-氧代-1，6-二氢吡啶-3-基)-1-((四氢-2H-吡喃-4-基)甲基)-1H-苯并[d]咪唑-5-基)甲基)氨基)-3-羟基丁酸异丙酯乙二磺酸盐的结晶水合物
TW200904409A (en) Azetidines
US20250248990A1 (en) Quinolines that modulate serca and their use for treating disease
US20240317746A1 (en) Crystalline forms of an azetidine parp1 inhibitor
CN118159535A (zh) 小分子sting拮抗剂
ES3035604T3 (en) Forms and compositions of inhibitors of plasma kallikrein
TW201713668A (zh) 吡啶化合物
CN117321042A (zh) 用于治疗炎症性疾病或癌症的氧代二氢吲哚化合物
JP2016513676A (ja) 化合物の多形および塩
JP5796872B2 (ja) 第Ｘａ因子阻害剤の結晶性塩
US20240262785A1 (en) Solid Forms, Salts and Polymorphs of Anti-fibrotic Compounds
KR20250144991A (ko) Apj 수용체 활성을 갖는 화합물의 염 및 고체 형태
WO2021211938A1 (en) Solid forms of inhibitors of plasma kallikrein